IP Library › Granted Patent US 12,692,313
Granted Patent B2
US 12,692,313 · App. 18/153,990 · Granted Jul 28, 2026

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

Inventors: Martin Pulé (London, GB); Leila Mekkaoui (London, GB); Persis Amrolia (London, GB); Sara Ghorashian (London, GB); Anne Kramer (London, GB); Gordon Cheung (London, GB)
Assignee: AUTOLUS LIMITED
C07K16/2803A61K40/11A61K40/31A61K40/4211C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K14/70596C07K16/3061C12N5/0636A61K2239/31A61K2239/38A61K2239/48C07K2317/56C07K2317/565C07K2317/567C07K2317/622C07K2317/73C07K2319/03C07K2319/33C07K2319/74C12N2510/00C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,313
App. No.
18/153,990
Filed
Jan 12, 2023
Granted
Jul 28, 2026
Kind
B2
Art Unit
1644
USPC
435/328
Abstract

There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.

Claims (15)

1 . A chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 10.

2 . A cell that comprises the CAR according to claim 1 .

3 . The cell according to claim 2 that is a hematopoietic stem cell or progenitor cell.

4 . The cell according to claim 2 that is a T cell or a natural killer (NK) cell.

5 . A composition that comprises a plurality of cells according to claim 2 .

6 . The composition according to claim 5 , further comprising a pharmaceutically acceptable carrier.

7 . A composition that comprises a plurality of cells according to claim 3 .

8 . The composition according to claim 7 , further comprising a pharmaceutically acceptable carrier.

9 . A composition that comprises a plurality of cells according to claim 4 .

10 . The composition according to claim 9 , further comprising a pharmaceutically acceptable carrier.

11 . A method for making a cell according to claim 2 , which comprises the step of transducing or transfecting a cell with a vector that comprises a nucleotide sequence that encodes a CAR that comprises the amino acid sequence of SEQ ID NO: 10.

12 . The method according to claim 11 , wherein the cell is a T cell or NK cell.

13 . The method according to claim 11 , wherein the cell is a hematopoietic stem cell or progenitor cell.

14 . A nucleic acid comprising a nucleotide sequence that encodes a chimeric antigen receptor (CAR), said CAR comprising the amino acid sequence of SEQ ID NO: 10.

15 . A vector that comprises the nucleic acid according to claim 14 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: PULE, MARTIN; MEKKAOUI, LEILA; AMROLIA, PERSIS; GHORASHIAN, SARA; KRAMER, ANNE; CHEUNG, GORDON
To: UCL BUSINESS PLC
Reel/Frame 063912/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: UCL BUSINESS LTD
To: AUTOLUS LIMITED
Reel/Frame 063912/0341 →
CHANGE OF NAME Recorded Jun 9, 2023
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 063956/0229 →
Priority Claims (1)
GB 1503742 · Mar 5, 2015 · national
Continuity (3)
Continuation 16573854 · Sep 17, 2019
Continuation 15555508 · Mar 4, 2016
Related Publication 20230220077A1 · Jul 13, 2023
References Cited (41)
US 10098926B2 · Pulé et al. · 2018 [cited by applicant]
US 10174099B2 · Pulé et al. · 2019 [cited by applicant]
US 10457730B2 · Pulé et al. · 2019 [cited by applicant]
US 10981970B2 · Pulé et al. · 2021 [cited by applicant]
US 11034750B2 · Pule et al. · 2021 [cited by applicant]
US 11091532B2 · Pulé et al. · 2021 [cited by applicant]
US 20170066838A1 · Pulé · 2017 [cited by examiner]
US 20170369550A1 · Pule et al. · 2017 [cited by applicant]
US 20180371054A1 · Pule et al. · 2018 [cited by applicant]
US 20190161531A1 · Pulé et al. · 2019 [cited by applicant]
US 20230019650A1 · Pulé · 2023 [cited by examiner]
US 20230027993A1 · Pulé · 2023 [cited by examiner]
US 20240301088A1 · Pulé · 2024 [cited by examiner]
US 20240374727A1 · Mansour · 2024 [cited by examiner]
US 20240408134A1 · Srivastava · 2024 [cited by examiner]
US 20250268941A1 · Pulé · 2025 [cited by examiner]
US 20250289891A1 · Kinna · 2025 [cited by examiner]
CN 102421800A · 2012 [cited by applicant]
CN 104159909A · 2014 [cited by applicant]
WO WO2010095031A2 · 2010 [cited by applicant]
WO WO2013126712A1 · 2013 [cited by applicant]
WO WO2014184143A1 · 2014 [cited by applicant]
Amrolia et al., Chimeric Antigen Receptor T Cells for ALL, Lancet, Feb. 7, 2015, vol. 385, pp. 488-490. [cited by applicant]
Brentjens, et al., CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci. Transl. Med., 5:177ra38 (2013). [cited by applicant]
Davila et al., “Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia,” Sci. Translat. Med. 6:224RA24 (2014). [cited by applicant]
Day et al., PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, Nature, 443:350-4 (2006). [cited by applicant]
EPO Communication Pursuant to Rule 161(1) and 162 EPC dated Oct. 17, 2017 in EP 16709529.8. [cited by applicant]
EPO Rule 71(3) Communication dated Nov. 9, 2018 in EP 16709529.8. [cited by applicant]
Ghorashian et al., A novel low affinity CD19CAR results in durable disease remissions and prolonged CAR T cell persistence without severe CRS or neurotoxicity in patients with paediatric ALL, [cited by applicant]
Guedan et al., Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation., [cited by applicant]
Imai et al., Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leuk., 18:676-84 (2004). [cited by applicant]
International Preliminary Report on Patentability, PCT/GB2016/050574, dated Sep. 5, 2017. [cited by applicant]
International Search Report and Written Opinion for PCT/GB2016/050574 (May 20, 2016). [cited by applicant]
Kochenderfer et al., Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies., J. Clin Oncol. 33:540-549 (2015). [cited by applicant]
Kochenderfer et al., Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor, J. Immunother., 2009, vol. 32, No. 7, pp. 689-702. [cited by applicant]
Lee et al., T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancets, 385(9967):517-28 (2015). [cited by applicant]
Lichtman et al., Chimeric Antigen receptor T-Cells for B-Cell malignancies, [cited by applicant]
Long et al., 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receiptors, [cited by applicant]
López-Alvarez et al., Association of monoclonal expansion of Epstein-Barr virus-negative CD158a+ NK cells secreting large amounts of gamma interferon with hemophagocytic lymphohistiocytosis, Clin. Vaccine Immunol., 16(1… [cited by applicant]
Maude et al., “Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia,” New Engl. J. Med. 371:1507-1517 (2014). [cited by applicant]
Qasim et al., Preliminary results for UCART19, an allogenic antiCD19 CAR T-cell product in a first-in-human trial (PALL) in pediatric patients with CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia, [cited by applicant]